首页> 外文期刊>Western Journal of Emergency Medicine >Higher Mallampati Scores Are Not Associated with More Adverse Events During Pediatric Procedural Sedation and Analgesia
【24h】

Higher Mallampati Scores Are Not Associated with More Adverse Events During Pediatric Procedural Sedation and Analgesia

机译:Mallampati评分较高与小儿手术镇静和镇痛过程中发生的更多不良事件无关

获取原文
           

摘要

Introduction: Procedural sedation and analgesia (PSA) is used by non-anesthesiologists (NAs) outside of the operating room for several types of procedures. Adverse events during pediatric PSA that pose the most risk to patient safety involve airway compromise. Higher Mallampati scores may indirectly indicate children at risk for airway compromise. Medical governing bodies have proposed guidelines for PSA performed by NAs, but these recommendations rarely suggest using Mallampati scores in pre-PSA evaluations. Our objective was to compare rates of adverse events during pediatric PSA in children with Mallampati scores of III/IV vs. scores of Mallampati I/II. Methods: This was a prospective, observational study. Children 18 years of age and under who presented to the pediatric emergency department (PED) and required PSA were enrolled. We obtained Mallampati scores as part of pre-PSA assessments. We defined adverse events as oxygen desaturation < 90%, apnea, laryngospasm, bag-valve-mask ventilation performed, repositioning of patient, emesis, and “other.” We used chi-square analysis to compare rates of adverse events between groups. Results: We enrolled 575 patients. The median age of the patients was 6.0 years (interquartile range = 3.1,9.9). The primary reasons for PSA was fracture reduction (n=265, 46.1%). Most sedations involved the use of ketamine (n= 568, 98.8%). Patients with Mallampati scores of III/IV were more likely to need repositioning compared to those with Mallampati scores of I/II (p=0.049). Overall, patients with Mallampati III/IV scores did not experience a higher proportion of adverse events compared to those with Mallampati scores of I/II. The relative risk of any adverse event in patients with Mallampati scores of III/IV (40 [23.8%]) compared to patients with Mallampati scores of I/II (53 [18.3%]) was 1.3 (95% confidence interval [0.91-1.87]).Conclusion: Patients with Mallampati scores of III/IV vs. Mallampati scores of I/II are not at an increased risk of adverse events during pediatric PSA. However, patients with Mallampati III/IV scores showed an increased need for repositioning, suggesting that the sedating physician should be vigilant when performing PSA in children with higher Mallampati scores.
机译:简介:手术室外的非麻醉医师(NA)使用了镇静镇痛(PSA)进行多种类型的手术。小儿PSA期间对患者安全构成最大风险的不良事件涉及气道损害。 Mallampati评分较高可能间接表明儿童有呼吸道受损的风险。医学理事机构已经提出了由NA进行PSA的指南,但是这些建议很少建议在PSA之前的评估中使用Mallampati评分。我们的目的是比较Mallampati评分为III / IV和Mallampati I / II评分的儿童小儿PSA期间的不良事件发生率。方法:这是一项前瞻性观察研究。招募了18岁及以下的小儿急诊科(PED)并需要PSA。在PSA评估之前,我们获得了Mallampati分数。我们将不良事件定义为:氧饱和度<90%,呼吸暂停,喉痉挛,进行袋气门面罩通气,重新定位患者,呕吐和其他。我们使用卡方分析来比较两组之间不良事件的发生率。结果:我们招募了575名患者。患者的中位年龄为6.0岁(四分位间距= 3.1,9.9)。 PSA的主要原因是骨折复位(n = 265,46.1%)。大多数镇静剂都使用氯胺酮(n = 568,98.8%)。与具有I / II Mallampati评分的患者相比,具有III / IV Mallampati评分的患者更有可能需要重新定位(p = 0.049)。总体而言,与具有I / II Mallampati评分的患者相比,具有Mallampati III / IV评分的患者没有发生更高比例的不良事件。 Mallampati评分为III / IV的患者(40 [23.8%])与Mallampati评分为I / II的患者(53 [18.3%])相比,发生任何不良事件的相对风险为1.3(95%置信区间[0.91- [1.87]。结论:小儿PSA期间III / IV的Mallampati评分与I / II的Mallampati评分相比,患不良事件的风险没有增加。但是,具有Mallampati III / IV评分的患者对重新定位的需求增加,这表明在对Mallampati评分较高的儿童进行PSA时,镇静医师应保持警惕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号